版本:
中国

BRIEF-Teva and regeneron announce global collaboration to develop Fasinumab

Sept 20 Teva Pharmaceutical Industries Ltd :

* To pay Regeneron $250 million upfront, share equally in global commercial value, ongoing research & development costs of about $1 billion

* Teva and Regeneron announce global collaboration to develop and commercialize Fasinumab, an investigational NGF antibody for chronic pain Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐